MTOR and hypertrophic cardiomyopathy: For example, although bag3 DCM (56), lamp2 hypertrophic cardiomyopathy (65), and anthracycline-induced cardiotoxicity models (66) benefit from mtor inhibition, the RRAGCS75Y knockin model does not but rather benefits from tfeb activation in cardiomyocytes (67).